NeuroSense Therapeutics Ltd. announced a collaboration in Alzheimer's Disease (AD) drug development with Genetika+. The multi-phase collaboration, which will commence in NeuroSense's currently ongoing Phase 2 AD clinical trial, leverages Genetika+'s technology that derives frontal cortex neurons from individual patients' blood to quantify drug-induced neuronal plasticity in vitro. The Genetika+ technology serves as a human AD disease model and will be used to correlate clinical response with cellular effects, for mechanistic drug insights and patient subset identification, supporting drug development and potentially commercialization.

This collaboration addresses key challenges in the development of drugs for AD, by promoting disease and drug mechanistic understanding, increasing the likelihood of success of AD drug development, and enabling the realization of precision medicine approaches. Distinguished by its innovative approach, NeuroSense's PrimeC therapy stands out in the landscape of AD treatments. Unlike conventional methods that predominantly target amyloid-beta (Aß), PrimeC adopts a multi-targeted strategy, concurrently addressing Aß aggregation, TDP-43, and other key disease-related pathologies.

This unique approach not only diversifies the therapeutic targets but also offers the potential for more potent treatment outcomes. With a well demonstrated synergistic mode of action, compelling pre-clinical and clinical data in related filed, and a strong safety profile, PrimeC is poised to potentially provide therapeutic efficacy in AD. Currently enrolling at the Stroke and Cognition Institute, Rambam Health Care Campus, Haifa, Israel, RoAD, NeuroSense's Phase 2 randomized, prospective double-blind, placebo-controlled study is designed to evaluate the therapeutic potential of PrimeC in treating AD.

The study will consist of 20 patients with mild to moderate non-familial AD. Participants will receive PrimeC or placebo (1:1) twice daily for 12 months and will be evaluated every three months. Endpoints include clinical outcome measurements, AD-related biomarkers, and markers of target engagement extracted from plasma and cerebrospinal fluid (CSF).

The study is expected to reveal the safety of PrimeC in AD, as well as shed light on the efficacy and biological activity of this combination therapy in this indication.